In today’s briefing:
- Medtronic’s Risky Split-Off: Limited Hedging, Oversubscription, and Potential Post-Tender Sell-Off Concerns
- IPO Rating: Electra Therapeutics Inc.
- Electra Therapeutics (ETRA) Targets $325 Million IPO to Advance Precision Immunology Pipeline
- ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio
- Medtronic’s 139% U.S. Ablation Growth — Can Sphere-9 Keep Taking Share?
- PBSV: Quarterly Results Prove Business Concept is Working
- PBSV: Quarterly Results Prove Business Concept is Working
Medtronic’s Risky Split-Off: Limited Hedging, Oversubscription, and Potential Post-Tender Sell-Off Concerns
- Medtronic’s exchange offer allows shareholders to swap MDT shares for MMED shares at a 7.53% premium, expiring October 9.
- Hedging is challenging due to limited borrow availability and high fees, with unhedged positions exposed to volatility risks.
- Odd-lot holders are prioritized in the tender, avoiding proration, while oversubscription is likely, affecting larger positions.
IPO Rating: Electra Therapeutics Inc.
- ✓ IPO Prophet Rating: 7.68/10 🏦 Deal Quality & Underwriters: 8.25/10 Electra Therapeutics is a late clinical-stage biotechnology company developing precision medicines that selectively deplete disease-driving immune cells through the signal regulatory protein family.
- Its lead candidate, ipsoprubart, is a first-in-class pan-SIRP antibody designed to target pathological myeloid and T cells while preserving unaffected immune populations.
- Ipsoprubart is being evaluated as a frontline treatment for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition with high mortality and limited treatment options.
Electra Therapeutics (ETRA) Targets $325 Million IPO to Advance Precision Immunology Pipeline
- Electra Therapeutics, Inc. (ETRA) is preparing to sell approximately 21.67 million shares of common stock on the Nasdaq Global Select Market at an expected price of $14.00 to $16.00 per share.
- At the $15.00 midpoint, the offering would raise approximately $325.0 million and value the clinical-stage biotechnology company at roughly $916.5 million.
- Jefferies, TD Cowen, Evercore ISI and Cantor are serving as joint book-running managers. The shares are expected to begin trading on Friday, September 18, 2026.
ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio
- Actinium Pharmaceuticals is a biology-driven radiotherapy company advancing candidates in oncology and conditioning for solid tumors and hematological malignancies.
- Its approach is expanding the reach of radiopharmaceuticals to novel target-isotope combinations in acute myeloid leukemia, solid tumors & conditioning.
- It favors Ac-225 isotopes in its oncology pipeline and I-131 for conditioning candidates.
Medtronic’s 139% U.S. Ablation Growth — Can Sphere-9 Keep Taking Share?
- Medtronic plc reported a robust start to fiscal year 2027 with first-quarter revenue reaching $9.8 billion, reflecting a 13.7% organic growth rate and adjusted earnings per share (EPS) of $1.45, both surpassing consensus expectations.
- This growth was broad-based across multiple business segments, geographic regions, and product lines, supported by an additional selling week contributing approximately $570 million to revenue.
- The company emphasized strength in its three largest operating units: Cardiac Rhythm Management (CRM), Cranial & Spinal Technologies (CST), and Surgical, which all posted solid results.
PBSV: Quarterly Results Prove Business Concept is Working
- Pharma-Bio Serv(PBSV) Company Sponsored Research Report
PBSV: Quarterly Results Prove Business Concept is Working
- Pharma-Bio Serv(PBSV) Company Sponsored Research Report
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
